Weight loss medication alert
The study indicates that the cardiovascular benefits of weight-loss medications, particularly GLP-1 receptor agonists such as "Ozempic," "Wegovy," and "Mounjaro," diminish after discontinuation. Individuals who continued with the treatment maintained an 18% reduction in the risk of cardiovascular events, whereas this risk increased by 14% after one year and 22% after two years of stopping the medication. The findings emphasize that discontinuing these drugs should be done with a well-planned treatment strategy in consultation with a healthcare professional, as sudden cessation may lead to weight regain and associated health changes related to blood pressure, cholesterol, and inflammation, thereby increasing the patient's risk of heart problems.
Notice: This Is an AI-Generated Summary
Comments (0)